Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzoyl peroxide

This article was originally published in The Tan Sheet

Executive Summary

FDA will seek comments on a proposed label warning for products containing the anti-acne ingredient in an upcoming Federal Register notice, agency staffers say. The notice also will recap a March 1992 recommendation by FDA's Dermatologic Drugs Advisory Committee meeting that benzoyl peroxide should remain on the market, but that product labeling should include a caveat that there is a lack of information on benzoyl peroxide's safety. Benzoyl peroxide was moved from Category I to Category III in August 1991 after studies indicated that it promoted tumors in rats.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel